Results 1 to 10 of about 23,953 (137)
Tigecycline is regarded as a last-resort treatment for multidrug-resistant Acinetobacter baumannii. However, tigecycline resistance in A. baumannii has increased worldwide. In this study, we investigated tigecycline heteroresistance in A.
Kwan Soo Ko, Jeongwoo Jo
exaly +3 more sources
Tigecycline for Severe Clostridium difficile Infection
Limited data suggest that tigecycline may be of value in the treatment of Clostridiumdifficile infection. We reviewed our experience using tigecycline to treat severe c.
Nizam Uddin
exaly +3 more sources
Probable Tigecycline‐Induced Acute Eosinophilic Pneumonia: A Case Report [PDF]
A 25‐year‐old man developed acute hypoxaemic respiratory failure after 21 days of tigecycline therapy for osteomyelitis caused by multidrug‐resistant organisms.
Annette Eom, Mutsumi Kioka
doaj +2 more sources
This study aimed to investigate the impact of tigecycline, the third generation tetracycline, on the antibiotic resistance development in environmental microbiota.
Ruyin Liu, Min Yang, Yu Zhang
exaly +3 more sources
New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and spread of multidrug-resistant bacteria that are commonly responsible for serious and life-threatening diseases. The need to develop new agents that effectively overcome existing mechanisms of resistance displayed by bacteria resistant to currently ...
James E, Frampton, Monique P, Curran
+7 more sources
Acinetobacter baumannii is one of the main pathogens causing nosocomial and community-acquired infections. Tigecycline is an important antibiotic for the treatment of multidrug-resistant A.
Ping Wang +5 more
doaj +1 more source
Background: Tigecycline and cefoperazone/sulbactam can cause coagulation disorders; tigecycline may also lead to hypofibrinogenemia, raising safety concerns.
Lei Zhang +6 more
doaj +1 more source
Acinetobacter baumannii is an important opportunistic pathogen of nosocomial infections. A. baumannii presently exhibits increasing antibiotic resistance, which poses great challenges to public health. The occurrence of tigecycline-resistant A. baumannii
Jiangang Zhang +8 more
doaj +1 more source
Infection with resistant pathogens can adversely affect clinical, microbiological and economic outcomes. New agents for the treatment of many such serious infections are acutely needed in hospital practice. Tigecycline is a novel glycylcycline antimicrobial for intravenous use.
Bhattacharya, M., Parakh, A., Narang, M.
+5 more sources
Background The development of tigecycline resistance in hypervirulent Klebsiella pneumoniae strains has resulted in decreased virulence that is associated with reduced production of capsular polysaccharides (CPS).
Suyeon Park, Hyunkeun Kim, Kwan Soo Ko
doaj +1 more source

